Study of SHR-A1921 plus Adebrelimab for advanced breast cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old with breast cancer that has spread or cannot be removed by surgery.
- Your cancer must be HR-positive, HER2-negative, and PD-L1 positive (your doctor can check this).
- You have tried at least 2 types of hormone therapy, including one with a CDK4/6 inhibitor, and your cancer has gotten worse.
- You have also had at least one round of chemotherapy for your advanced cancer.
- You have at least one tumor that can be measured on a scan, and your doctor expects you to live at least 3 more months.
- Your organs (like liver, kidneys, and bone marrow) are working well enough, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
This trial tests a combination of two drugs (SHR-A1921 and adebrelimab) for people with advanced non-small cell lung cancer whose cancer has grown after standard first-line treatment. The goal is to see if this new combination can help shrink tumors or slow their growth.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.